HIF1A and melanoma: Pivaloyloxymethyl butyrate (Pivanex, AN-9) is the other short-chain fatty acid that is in phase I/II clinical trials for malignant melanoma, and AN-9 exhibited antimetastatic and antiangiogenic activities via decreasing vascularization, bFGF expression, and HIF-1α [257].